Analysts predict that Abeona Therapeutics Inc (NASDAQ:ABEO) will report earnings per share (EPS) of ($0.17) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Abeona Therapeutics’ earnings, with estimates ranging from ($0.17) to ($0.16). Abeona Therapeutics posted earnings of ($0.14) per share in the same quarter last year, which suggests a negative year over year growth rate of 21.4%. The business is expected to announce its next quarterly earnings results on Monday, August 9th.
On average, analysts expect that Abeona Therapeutics will report full year earnings of ($0.67) per share for the current financial year, with EPS estimates ranging from ($0.69) to ($0.66). For the next fiscal year, analysts anticipate that the company will report earnings of ($0.63) per share, with EPS estimates ranging from ($0.68) to ($0.55). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Abeona Therapeutics.
Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings data on Tuesday, May 18th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.02.
Shares of Abeona Therapeutics stock traded down $0.01 during trading hours on Tuesday, hitting $1.84. 2,147 shares of the company were exchanged, compared to its average volume of 3,076,083. Abeona Therapeutics has a 1 year low of $0.99 and a 1 year high of $3.79. The company has a quick ratio of 2.17, a current ratio of 2.17 and a debt-to-equity ratio of 0.01. The firm has a 50-day simple moving average of $1.61. The firm has a market capitalization of $182.19 million, a PE ratio of -3.30 and a beta of 1.43.
In related news, Director Sco Capital Partners Llc sold 80,000 shares of the company’s stock in a transaction on Thursday, March 18th. The stock was sold at an average price of $2.23, for a total transaction of $178,400.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CAO Edward Carr sold 20,445 shares of the company’s stock in a transaction on Thursday, April 1st. The stock was sold at an average price of $1.85, for a total value of $37,823.25. Following the transaction, the chief accounting officer now directly owns 226,291 shares in the company, valued at approximately $418,638.35. The disclosure for this sale can be found here. Insiders have sold 180,854 shares of company stock worth $364,138 in the last ninety days. 15.40% of the stock is currently owned by corporate insiders.
Institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC grew its holdings in Abeona Therapeutics by 633.9% in the fourth quarter. Renaissance Technologies LLC now owns 1,322,903 shares of the biopharmaceutical company’s stock valued at $2,077,000 after purchasing an additional 1,142,652 shares during the last quarter. Virtu Financial LLC grew its holdings in Abeona Therapeutics by 217.0% in the fourth quarter. Virtu Financial LLC now owns 118,030 shares of the biopharmaceutical company’s stock valued at $185,000 after purchasing an additional 80,798 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Abeona Therapeutics by 7.6% in the fourth quarter. Bank of New York Mellon Corp now owns 280,733 shares of the biopharmaceutical company’s stock valued at $441,000 after purchasing an additional 19,947 shares during the last quarter. BlackRock Inc. grew its holdings in Abeona Therapeutics by 5.0% in the fourth quarter. BlackRock Inc. now owns 4,090,830 shares of the biopharmaceutical company’s stock valued at $6,423,000 after purchasing an additional 193,963 shares during the last quarter. Finally, Wells Fargo & Company MN grew its holdings in Abeona Therapeutics by 26.9% in the fourth quarter. Wells Fargo & Company MN now owns 80,942 shares of the biopharmaceutical company’s stock valued at $127,000 after purchasing an additional 17,168 shares during the last quarter. 31.60% of the stock is currently owned by institutional investors.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Recommended Story: What are the qualifications of a portfolio manager?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.